Open AccessCardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat
Author(s) -
Miguel Teixeira,
Paulo Rodrigues-Santos,
Patrícia Garrido,
Elı́sio Costa,
B. Parada,
José Sereno,
Rui Alves,
Luı́s Belo,
Frederico Teixeira,
Alice Santos-Silva,
Flávio Reis
Publication year - 2012
Publication title -
journal of pharmacy and bioallied sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.268
H-Index - 36
eISSN - 0976-4879
pISSN - 0975-7406
DOI - 10.4103/0975-7406.92743
Subject(s) - medicine , erythropoietin , angiogenesis , inflammation , heart failure , nephrectomy , apoptosis , lesion , anemia , kidney , pharmacology , immunology , endocrinology , surgery , biology , biochemistry
Recombinant human erythropoietin (rhEPO) therapy under circumstances of moderate chronic renal failure (CRF), with yet lower kidney and heart lesion, may have a protective cardiac effect beyond the correction of anemia, whose mechanism deserves better elucidation, namely by clarifying the impact on gene expression profile of markers of apoptosis, inflammation, proliferation, angiogenesis, and lesion/stress in the heart.